SCHEMBL25348161

SCHEMBL25348161

COC(=O)c1cc(Br)nc2c1CCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.51
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 4/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 3/20 0.43
GAA P10253 3/20 0.43
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
SPR P35270 1/20 0.41
MAPK10 P53779 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TP53 P04637 2/20 0.39
MMP13 P45452 1/20 0.39
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18320814 0.83 ACHE (0.52) ACHEKDM4EALDH1A1HPGDMAPT
SCHEMBL18320624 0.83 ACHE (0.52) ACHEKDM4EALDH1A1HPGDMAPT
SCHEMBL26104929 0.82 ACHE (0.54) ACHEKDM4EALDH1A1HPGDMAPT
SCHEMBL14206640 0.82 ACHE (0.57) ACHEKDM4EALDH1A1HPGDMAPT
SCHEMBL25353988 0.75 L3MBTL1 (0.38) ACHEKDM4EALDH1A1HPGDMAPT
SCHEMBL31396038 0.73 ACHE (0.48) ACHEKDM4EALDH1A1HPGDMAPT
SCHEMBL18584387 0.73 ACHE (0.45) ACHEKDM4EALDH1A1HPGDMAPT
SCHEMBL29393554 0.73 ACHE (0.45) ACHEKDM4EALDH1A1HPGDMAPT
SCHEMBL25348951 0.72 L3MBTL1 (0.39) ACHEKDM4EALDH1A1HPGDL3MBTL1
SCHEMBL25348307 0.72 L3MBTL1 (0.39) ALDH1A1HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-05-22 US disclosed
EP-4476219-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene, Ltd. (KY) 2024-12-18 EP disclosed
CN-118696043-A Heterocyclic compounds, compositions thereof and methods of treatment therewith 百济神州有限公司 2024-09-24 CN disclosed
WO-2023151642-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 WO disclosed
WO-2023151636-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH NFATC1, GZMB, IFNG ACHE 300/4885KDM4E 996/4885ALDH1A1 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.